(Q38089623)

28 August 2017

title

LDL cholesterol goals in high-risk patients: how low do we go and how do we get there? (English)

1 reference

28 August 2017

3

John J P Kastelein

1 reference

28 August 2017

Joost Besseling

1

1 reference

28 August 2017

Julian van Capelleveen

series ordinal

2

1 reference

28 August 2017

G Kees Hovingh

series ordinal

4

1 reference

28 August 2017

publication date

1 March 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

73

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

293-301

1 reference

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

ESC/EAS Guidelines for the management of dyslipidaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evalu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

A comparative analysis of three widely used lipid management guidelines in the EPIC-Norfolk cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Prediction of Coronary Heart Disease Using Risk Factor Categories

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Risk factors for intracerebral hemorrhage in a pooled prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

A receptor-mediated pathway for cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Lipid goals among patients with diabetes or metabolic syndrome: Lipid Treatment Assessment Project (L-TAP) 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki Prefectural Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Large-scale cohort study on the relationship between serum lipid concentrations and risk of cerebrovascular disease under low-dose simvastatin in Japanese patients with hypercholesterolemia: sub-analysis of the Japan Lipid Intervention Trial (J-LIT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Familial hypercholesterolemia: present and future management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Attainment of Canadian and European guidelines’ lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Antisense oligonucleotides for the treatment of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Antisense therapy in the treatment of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Lapaquistat Acetate: Development of a Squalene Synthase Inhibitor for the Treatment of Hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Thyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0028-0

Dalcetrapib , a cholesteryl ester transfer protein modulator

21 January 2018

1 reference

12 December 2020

Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions

1 reference

12 December 2020

Prevention of coronary heart disease with pravastatin.

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

12 December 2020

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis (the SEAS trial).

1 reference

12 December 2020

10.1007/S40265-013-0028-0

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1037488469

0 references

1 reference